Key facts
- It has raised $4.2M; the latest was Early Stage VC ($4.2M) in Nov 2025.
- Notable investors include Linghang Ventures.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for BDSyn Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for BDSyn Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BDSyn Bio
Manufacturer of vaccine adjuvant technologies designed to enhance the safety, potency, and performance of next-generation immunisation products. The company offers single-structure adjuvants produced under stringent manufacturing standards alongside tailored formulation development and immunological assessment, enabling global vaccine developers to access reliable adjuvant supply and achieve superior efficacy in vaccine research and production.
- Sector
- Healthcare
- HQ
- Chongqing, China
- Founded
- 2023
- Website
- bdsynbiotech.com/
- Ownership
- Privately Held (backing)
BDSyn Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BDSyn Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BDSyn Bio in its N-PORT filings yet. We sweep new filings monthly.